Accuray Incorporated (NASDAQ:ARAY ) Q4 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Ali Pervaiz - Senior VP & CFO Suzanne Winter - President, CEO & Director Conference Call Participants Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Operator Welcome to the Accuray Fourth Quarter Fiscal 2025 Fi...
MADISON, Wis. , July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended June 30, 2025, during a conference call hosted by company management at 1:30 p.m.
MADISON, Wis. , June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82....
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the trea...
Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife ® System, expanding access to stereotactic radiosurg...
Accuray has consistently struggled with execution, and now tariffs threaten to significantly impact the company's business in China - it's most promising growth driver. Recent Q3 results showed revenue growth but were overshadowed by weaker guidance and declining orders, particularly impacted by U.S.-China tariffs. The competition in China is intensifying, with local and global players ramping ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.